Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Investor Presentation (May 2026)
34 slides from Autolus Therapeutics's investor presentation, May 2026
Slide 1: Developing Next Generation Programmed T Cell Therapies
Developing Next Generation Programmed T Cell Therapies May 2026 For Investor communication only. Not for use in Autolus.com product promotion.
Slide 2: Disclaimer
Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fact
Slide 3: Autolus is positioned for value creation
Developing and Delivering a New Generation of T Cell Therapies Autolus is positioned for value creation Obe-cel product franchise supports multiple growth opportunities Initial Indication: Adult r/r B-ALL Pipeline expansion opportunities Strong Execution in First Year of Launch grow future commercia
Slide 4: Autolus is a leader in CAR T manufacturing & product delivery
Developing and Delivering a New Generation of T Cell Therapies Autolus is a leader in CAR T manufacturing & product delivery Executing on manufacturing and product delivery in the first year of launch: Manufacturing success rate >90% Fast, reliable and consistent product delivery No capacity l
Slide 5: AUCATZYL®
AUTOLUS’ FIRST APPROVED PRODUCT AUCATZYL® A potentially best-in-class, standalone CD19 CAR T cell therapy
Slide 6: AUCATZYL® is gaining traction in US and UK markets
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL® is gaining traction in US and UK markets AUCATZYL Global Net Product Revenue 2026 Expectations Q1 2026: $26.2 million FY 2026 Net Product Revenue: $120-$135 million Increase commercial footprint in the US to more than 80 treatm
Slide 7: AUCATZYL geographic growth opportunities in ALL
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL geographic growth opportunities in ALL Expansion Conditional marketing authorization in the UK received April 2025 UK Launch Q1 2026 Successful NICE pricing and reimbursement process Nov 2025 AUCATZYL available in routine
Slide 8: FELIX trial published in New England Journal of Medicine
Developing and Delivering a New Generation of T Cell Therapies FELIX trial published in New England Journal of Medicine1 Favourable response rate and tolerability, despite challenging patient population High overall response rate with deep molecular responses Excellent tolerability profile • Durable
Slide 9: Data continue to show long term remissions in r/r adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Data continue to show long term remissions in r/r adult B-ALL At 24 months, overall survival probability was 46.0% Jae H Park et al, EHA 2025, oral presentation #S113 9
Slide 10: Duration of response: median 42.6 months at last data cut
Developing and Delivering a New Generation of T Cell Therapies Duration of response: median 42.6 months at last data cut More than half of patients still in remission at 24 months Jae H Park et al, EHA 2025, oral presentation #S113 10
Slide 11: ASTCT 2026: AUCATZYL® patient characteristics in real world setting
Developing and Delivering a New Generation of T Cell Therapies ASTCT 2026: AUCATZYL® patient characteristics in real world setting ROCCA Consortium registry covers approximately 60% of U.S. commercial patients at data cutoff of January 2026 No patient drop off between 1st & 2nd infusion 96 patients
Slide 12: ASTCT 2026: AUCATZYL® real world data consistent with FELIX pivotal trial
Developing and Delivering a New Generation of T Cell Therapies ASTCT 2026: AUCATZYL® real world data consistent with FELIX pivotal trial ROCCA Consortium registry covers approximately 60% of U.S. commercial patients at data cutoff of January 2026 Bone Marrow Disease Response 100% 80% 60% 69% 66% 40%
Slide 13: Expanding the obe-cel opportunity
Expanding the obe-cel opportunity Deep value program with potentially broad applicability
Slide 14: Pipeline supports growth with multiple development opportunities
Developing and Delivering a New Generation of T Cell Therapies Pipeline supports growth with multiple development opportunities Near-Term Growth Drivers Product Indication Target Preclinical Phase 1 Phase 2/Pivotal Approved Status AUCATZYL® FDA, MHRA^ & EC Adult ALL CD19 (obe-cel) approved† obe-cel
Slide 15: Growing the obe-cel franchise commercial opportunity
Developing and Delivering a New Generation of T Cell Therapies Growing the obe-cel franchise commercial opportunity Robust clinical database and demonstrated commercial capabilities position Autolus for efficient path in new indications Graphic is illustrative, not to scale Significant ~300,0003 Mar
Slide 16: Pediatric r/r B-ALL development strategy
Developing and Delivering a New Generation of T Cell Therapies Pediatric r/r B-ALL development strategy Regenerative Medicine Advanced Therapy (RMAT) designation supports development pathway Development Rationale: CATULUS Phase 1 CATULUS Phase 2 High Unmet Medical Need • 30 patients, SAT • Kymriah a
Slide 17: CATULUS Phase 1 data support progressing into Phase 2
Developing and Delivering a New Generation of T Cell Therapies CATULUS Phase 1 data support progressing into Phase 2 Safety profile of obe-cel in pediatric patients consistent with that previously reported in adults *One patient experienced both Grade 3 CRS and Grade 3 ICANS. ‡Time to onset (days) =
Slide 18: CATULUS data demonstrate promising initial efficacy in pediatric patients
Developing and Delivering a New Generation of T Cell Therapies CATULUS data demonstrate promising initial efficacy in pediatric patients At median follow-up of 8.8 months in pediatric r/r B-ALL patients: ORR was 95.5%; CR was achieved in 90.9% Swimmer plot showing disease assessments in the B-ALL co
Slide 19: Opportunity in U.S. to be the preferred treatment for all age groups in r/r B-ALL
Investor Event: Spotlight on ALL Business Opportunity in U.S. to be the preferred treatment for all age groups in r/r B-ALL with pediatric label expansion Disease Stages Ages Refractory 1L Relapse 2L+ Relapse 0-18* Obe-cel 18+ 0-25 Tisa-cel 26+ 0-18 Brexu-cel 18+ Source: USPI Features, Kymriah *Assu
Slide 20: MOA and commercial capabilities are key differentiators in AID
Developing and Delivering a New Generation of T Cell Therapies MOA and commercial capabilities are key differentiators in AID Obe-cel is the only CD19 CAR approved in other indications that is now being tested for autoimmune disease Autolus Potential Advantage Favorable tolerability to drive accepta
Slide 21: CARSLYLE: Obe-cel shows promise as a new approach for SLE/LN
Developing and Delivering a New Generation of T Cell Therapies 21 CARSLYLE: Obe-cel shows promise as a new approach for SLE/LN 50 million cell dose selected as recommended Phase 2 dose Patient population: • Patients were significantly impaired with their kidney function and had across the board some
Slide 22: CARSLYLE: Obe-cel is well tolerated with no ICANS or Grade ≥2 CRS
Developing and Delivering a New Generation of T Cell Therapies CARSLYLE: Obe-cel is well tolerated with no ICANS or Grade ≥2 CRS Infused adult patients, 50M (n=6) Infused adult patients, 100M (n=3) Any grade, n (%) Grade ≥3, n (%) Any grade, n (%) Grade ≥3, n(%) CRS 3 (50.0) 0 3 (100) 0 ICANS 0 0 0
Slide 23: 5 of 6 patients achieved DORIS with median onset of 5.1 months
Developing and Delivering a New Generation of T Cell Therapies 5 of 6 patients achieved DORIS with median onset of 5.1 months Swimmer plot showing DORIS over time in the 50M adult cohort (n=6) Patient 1 Patient 2 50M adults (n=6) Patient 3 Patient 4 Patient 5 Patient 6 1 2 3 4 5 6 7 8 9 10 11 12 Tim
Slide 24: Clinically meaningful reduction in SLEDAI-2K score observed
Developing and Delivering a New Generation of T Cell Therapies Clinically meaningful reduction in SLEDAI-2K score observed 50M adult cohort (n=6) 100M adult cohort (n=3) Patient 1 Patient 2 Patient 3 Patient 1 Patient 2 30 30 30 30 30 25 25 25 25 25 SLEDAI-2K score SLEDAI-2K score SLEDAI-2K score SL
Slide 25: Lupus nephritis development strategy
Developing and Delivering a New Generation of T Cell Therapies Lupus nephritis development strategy First Approval Label Expansion Leveraging a fast to market strategy CARLYSLE Trial LUMINA Trial Ph3 Randomized Development Rationale Phase 1 Phase 2 Controlled vs SoC • LN is assessed by quantitative
Slide 26: Phase 2 LUMINA trial supports efficient path to market
Developing and Delivering a New Generation of T Cell Therapies Phase 2 LUMINA trial supports efficient path to market Evaluating severe, refractory lupus nephritis (LN) Obe-cel Obe-cel Manufacturing Infusion Monthly safety and L Day-5 Day 1 efficacy follow-up Screening Leukapheresis Lymphodepletion
Slide 27: Multiple sclerosis development strategy
Developing and Delivering a New Generation of T Cell Therapies Multiple sclerosis development strategy • Anticipate a Establish Phase 1 Clinical Proof of Concept in MS randomised phase 2/3 study design as 3 x 6 dose escalation design - a higher dose path to approval may be required for CNS effect In
Slide 28: BOBCAT study population represents the highest unmet need in MS
Developing and Delivering a New Generation of T Cell Therapies BOBCAT study population represents the highest unmet need in MS Aspirational – improving disability and moving back on 1. Progressive forms of MS EDSS timeline including all forms of Transformational – halting disease progressive MS with
Slide 29: BOBCAT Phase 1 study design
Developing Next Generation Programmed T Cell Therapies BOBCAT Phase 1 study design Sample size: 12-18 patients infused with obe-cel Dosing: Standard Flu/Cy based preconditioning and a single infusion of 100 or 200 million CART cells and flexibility to adjust dose up or down Primary endpoint: •Safety
Slide 30: Upcoming milestones
Developing and Delivering a New Generation of T Cell Therapies Upcoming milestones Anticipated Milestone or Catalyst Anticipated Timing Longer-term follow up data from CARLYSLE trial Year End 2026 Initial clinical data from BOBCAT Phase 1 trial in progressive MS Year End 2026 Initial clinical data f
Slide 31: Financial Highlights
Financial Highlights
Slide 32: Financial summary – key metrics
Developing and Delivering a New Generation of T Cell Therapies Financial summary – key metrics* Turn to positive gross margin occurred in Q1 2026 and is expected to steadily improve USD ($’ 000) Q1 2026 Q1 2025 Variance Product revenue, net 26,218 8,982 17,236 Cost and operating expenses: Cost of sa
Slide 33: Path to profitability in the ALL business
Developing and Delivering a New Generation of T Cell Therapies Path to profitability in the ALL business Optimizing the operating model and driving cost efficiency Cost reduction initiatives aimed at driving Peak: expect gross profit gross profit margin improvements margin of 65-70% Actions expected
Slide 34: Thank you
Thank you Investor Contact: A.Cray@autolus.com Executive Director, Investor Relations & External Communications Autolus.com
Autolus Therapeutics — Investor Presentation (May 2026) on 6ix